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Introduction: The role of stereotactic body radiation therapy (SBRT) 
in patients with metastatic lung cancer harboring epidermal growth 
factor receptor (EGFR) mutations is not deﬁned. We evaluated the 
pattern of failure in patients receiving tyrosine kinase inhibitor (TKI) 
therapy to identify candidates for consolidation SBRT.
Methods: Computed tomography scans were reviewed in a cohort 
of EGFR-mutant patients enrolled on prospective TKI trials. Initial 
progression in sites of original disease (primary/metastatic) or new 
sites was classiﬁed as original site failure (OF) or distant site failure 
(DF), respectively. Simultaneous OF/DF was labeled ODF. Disease 
characteristics were analyzed for associations with patterns of failure 
using actuarial competing risks methodology.
Results: Complete serial imaging was available in 49 patients with 
measurable disease. Median time to any progression was 8.3 months. 
The majority failed initially in original disease sites with OF, ODF, and 
DF frequencies being 47.0%, 32.6%, and 20.4%, respectively. Primary 
tumor size was the most signiﬁcant predictor of OF in univariate and 
multivariate analysis (p = 0.004). Median time to progression was 3 
months shorter in patients with OF compared with DF. Ten patients 
(20%) were retroactively classiﬁed as consolidation SBRT candidates 
based on the extent of disease at time of best response to TKI therapy, 
and in seven of these, initial progression occurred in original tumor sites.
Conclusion: Initial progression of TKI-treated cancers occurred pre-
dominantly in original disease sites. Consolidation SBRT was judged 
feasible in a subset of patients following maximum TKI response and 
may have prevented oligoprogression in most of these. In addition, 
we hypothesize that consolidation SBRT for residual disease could 
delay subsequent metastatic reseeding.
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Oncogene-driven cancers represent a unique subset of non–small-cell lung cancer (NSCLC) that responds 
well to targeted tyrosine kinase inhibitors (TKI). Mutated 
epidermal growth factor receptor (EGFR) is the most com-
mon targetable oncogene found in NSCLC.1,2 Clinically, the 
use of TKI in patients with EGFR-mutant metastatic NSCLC 
is associated with an objective and often dramatic response 
rate in approximately 70% of cases, compared with response 
rates of 20% to 30% seen with the use of conventional che-
motherapy. Treatment with EGFR TKI is associated with 
a median progression-free survival (PFS) of 8–13 months, 
which is signiﬁcantly longer than observed with chemother-
apy (3–5 mo).3–7 However, the development of drug resistance 
remains an important challenge to the success of TKI therapy 
in maintaining durable disease control. This occurs as a result 
of the growth of TKI-resistant clones that most often arise 
within sites of persistent disease (primary and metastatic) in 
originally involved anatomical sites.8,9 Interestingly, studies 
have demonstrated that clones can simultaneously arise with 
different resistance mechanisms at different sites of residual 
disease, complicating strategies toward designing effective 
combinations of targeted systemic therapies.9–14 In addition to 
causing disease progression in the original sites, the growth of 
resistant clones can lead to systemic reseeding, which results 
in the development of distant failures (DFs) in new sites of 
disease, as has been shown for various types of cancer includ-
ing prostate cancer and soft-tissue sarcomas.15–17
To improve disease control in the treatment of pro-
gressive oligometastatic or oligoprogressive disease, there 
has been an increased interest in evaluating the beneﬁts of 
local therapies, such as stereotactic body radiation therapy 
(SBRT).18–25 SBRT is an advanced radiation therapy modal-
ity that involves the delivery of ablative individual doses 
of radiation to tumors in various extracranial sites.26–28  
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A number of studies have shown that SBRT can achieve 
high rates of local control of treated lesions in patients 
with limited pulmonary, hepatic, adrenal, and spinal metas-
tases.29–33 SBRT has also been employed in patients with 
oncogene-driven NSCLC who experience oligoprogres-
sion.22,34 Because progression can result in reseeding, there 
is a rationale for upfront consolidation SBRT before pro-
gression occurs, but this has been understudied. To identify 
potential candidates for consolidation SBRT, it is important 
to determine the pattern of failure on TKI therapy. In this 
study, we performed a detailed analysis of the pattern of 
failure in TKI-treated metastatic EGFR-mutant NSCLC and 
sought to identify predictors of failure in original sites of 
disease. In addition, we asked whether a subset of patients 
may exist in which TKI response converts diffuse metastatic 
disease at initial presentation to a residual disease state that 
would be amenable to consolidation SBRT.
PATIENTS AND METHODS
Patients
We reviewed the charts of metastatic EGFR-mutant 
NSCLC patients who were enrolled on prospective studies 
investigating the beneﬁts of geﬁtinib, erlotinib, and afatinib 
at the Massachusetts General Hospital between 2006 and 
2012.3,35,36 Patients eligible for this review had a pathologi-
cally conﬁrmed diagnosis of NSCLC. Activating EGFR muta-
tions (L858R, exon 19 deletion) were veriﬁed either through 
direct sequencing or allele-speciﬁc polymerase chain reac-
tion assays. All patients assessed had measurable metastatic 
disease identiﬁed on clinical and/or radiologic examination 
before initiation of TKI therapy. Baseline and surveillance 
imaging studies demonstrating initial disease extent, disease 
response after TKI therapy, and eventual disease progression 
were available for all included patients and were used to ana-
lyze the patterns of failure. Baseline clinical characteristics 
were collected from electronic records, including age at diag-
nosis, sex, smoking history, tumor histology, prior systemic 
therapy, prior palliative radiotherapy treatment of brain or 
bone metastasis, status of primary and regional nodal disease, 
and the number and sites of metastatic disease. This review 
was approved by the institutional review board.
Treatment Outcome and Pattern 
of Failure Analysis
Baseline imaging with computed tomography (CT) of 
the chest, abdomen, and pelvis, with or without positron emis-
sion tomography was obtained for all patients before initiating 
TKI therapy. Follow-up scans were typically performed every 
8 weeks. Imaging of the brain at either baseline or on treat-
ment was not mandatory for any patient but was performed 
when clinically indicated or at the discretion of the treat-
ing physician. For the purposes of analyzing the patterns of 
failure, the imaging studies for all patients included in this 
study were reviewed by a senior thoracic radiologist. All serial 
scans were evaluated for sites of original disease (primary and 
metastatic), disease response to TKI, and tumor progression 
in original (primary and metastatic) or new sites of disease. 
Primary, nodal, and metastatic disease responses, except for 
spine metastases, were assessed using Response Evaluation 
Criteria in Solid Tumors (RECIST) 1.1 guidelines.37
Original site failure (OF) was deﬁned as evidence of 
progressive disease within the primary and/or individual 
metastatic lesions that were present before initiation of TKI 
therapy. DF was deﬁned as the radiographic appearance of 
a new metastatic lesion having a dimension of at least 1 cm 
in a site that was not identiﬁed at disease presentation before 
initiating TKI therapy. For primary lung lesions, intrathoracic 
failure at least 2 cm away from known disease was also scored 
as DF. In some cases, DF was detected clinically in patients 
who developed new biopsy-proven cutaneous metastases that 
were not identiﬁed radiographically. Original and distant site 
failure (ODF) was deﬁned by evidence of OF and DF detected 
simultaneously on follow-up imaging.
SBRT Eligibility
The CT scan at the maximum response to TKI was ret-
rospectively assessed by a radiation oncologist in this study to 
determine if the extent of residual disease was hypothetically 
amenable to consolidation SBRT. The criteria used for judg-
ing SBRT eligibility were based on institutional guidelines and 
adapted from the study by Weickhardt et al.22 Patients were con-
sidered SBRT eligible if their residual metastatic disease bur-
den was limited to ﬁve or less sites (in addition to the primary 
site) and located within the lungs (1–3 lesions plus primary, 
size 1–5 cm), liver (1–4 lesions, 1–5 cm), adrenals (1–2 lesions, 
1–4 cm), and/or spine (1–2 levels of 1–3 vertebral bodies each). 
Patients with residual hilar or mediastinal regional lymph node 
disease (deﬁned as nodal size >1 cm in short-axis diameter on 
CT scan) were deemed SBRT-ineligible because of concerns 
of increased toxicity with treatment of central normal struc-
tures and recent evidence showing lack of beneﬁt from SBRT 
for oligometastasis in node-positive patients.38 Patients with a 
malignant pleural effusion before the start of TKI therapy were 
only considered eligible for SBRT if there was complete radio-
graphic resolution of the effusion while on TKI therapy.
Statistical Analysis
Time to progression was measured from the time of TKI 
initiation until progression on the same targeted therapy using 
RECIST criteria. All patients experienced progression before 
death. Actuarial univariate and multivariate analyses of asso-
ciation of disease characteristics with time to progression were 
performed using competing risk methodology. For any of the 
three patterns of failure (OF, DF, and ODF) the other two pat-
terns were deﬁned as competing events. Multinomial (polyto-
mous) logistic regression was used to estimate the probability 
of progression for all three patterns of failure. All analyses 
were performed with Stata version 13.1 software (StataCorp, 
College Station, TX). All p values were two-sided.
RESULTS
Clinical Features
Out of 200 patient records reviewed for this study, 53 had 
complete serial CT scans for a review of the pattern of failure, 
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and 49 had measurable disease before TKI initiation. Median 
age was 64 years (range, 26–89). There were 32 females and 
17 males. As shown in Table 1, the lung was the most com-
mon site harboring metastatic disease at presentation irrespec-
tive of failure pattern (see below), followed by bone, brain, 
liver, and other sites. The majority of patients had metastases 
in two or three organs, and only eight patients presented with 
an “oligometastatic” state of 1–5 metastases. Five patients had 
undergone resection of primary disease before commencing 
TKI therapy. Twelve and seven patients had undergone radia-
tion therapy for brain and bone metastases, respectively, and 
10 patients had prior chemotherapy.
Pattern of Disease Failure
At a median follow-up of 52 months, all patients devel-
oped progression with a median time to progression of 8.3 
months (range, 1.4–63 mo). The cumulative actuarial rates 
of any progression at 12 and 18 months were 65% and 80%, 
respectively. Initial sites of failure are shown in Table 2. 
Almost 50% of patients experienced isolated OF. The lung 
was the most common site of initial progression, and 45% of 
patients progressed in the primary site (with or without con-
current metastatic sites). Eight of the nine cases with regional 
nodal failure occurred in the 18 patients (44%) who had 
residual nodal disease following maximal response to TKI. In 
contrast, none of the 12 patients with node-negative disease at 
presentation developed regional nodal failure.
The median time to maximum response after TKI ini-
tiation was 2.7 months (range, 0–12 mo). Only one patient 
had disease progression at time of ﬁrst surveillance scan, 1.4 
months after TKI administration. The median time to maxi-
mum response was 2.5, 2.7, and 3.5 in patients with OF, 
ODF, and DF, respectively. The median time to progression 
was 8.6 months (range, 1.4–63.3 mo) in patients who devel-
oped OF and 6.6 months (range, 3.4–34.1 mo) in patients 
with ODF. Median time to progression was longer in patients 
who experienced DF measuring 12.3 months (range, 3.1–36.2 
mo), although this difference was not statistically signiﬁcant. 
Similarly, time to OF or ODF was shorter than time to DF, as 
illustrated in Figure 1A. The 12-month and 18-month cumula-
tive rates of progression in patients who developed OF, ODF, 
and DF were 30% and 24%, 10% and 40%, 24% and 16%, 
respectively. Moreover, the median time to progression mea-
sured from time of maximum response to TKI in patients with 
OF, ODF, and DF was 4.6, 3.9, and 7.1 months, respectively. 
It seems that although the median time to maximum TKI 
response was 1 month longer in patients who develop DF, the 
time to disease progression following maximal response was 
still longer in patients with DF.
Predictors of Original Site Failure
Univariate analysis identiﬁed the size of the primary 
lung tumor at presentation as the strongest risk factor asso-
ciated with OF (hazard ratio, 1.30; 95% conﬁdence interval, 
1.08–1.57; p = 0.004), and this was conﬁrmed in multivari-
ate analysis (Table 3). The relationship between primary lung 
tumor size and each of the three initial failure types was mod-
eled and is shown in Figure 1B. The larger the primary tumor 
size, the more likely it was for patients to develop OF. In 12 of 
14 patients with primary tumor size greater than the median of 
2.8 cm, initial failure occurred at the primary site. The median 
time to progression in patients with primary tumor greater and 
less than 2.8 cm was 7.8 and 9.2 months, respectively.
Analysis of Potential Eligibility 
for Consolidation SBRT
We assessed treatment responses to evaluate how effec-
tive TKI therapy might be in converting extensive metastatic 
disease at presentation to residual oligometastatic disease 
that could be targeted with consolidation SBRT. After TKI 
therapy, 10 (20%) patients experienced a maximal response 
leaving them with residual metastatic disease burden that was 
deemed amenable to consolidation SBRT (Table 4). An addi-
tional patient had a complete remission in all sites. In eight 
patients, residual disease included targets for thoracic SBRT. 
The ﬁrst site of failure was OF in seven patients, whereas 
the other three patients experienced ODF or DF. In these 10 
patients, the median time to any failure of 11.8 months (95% 
conﬁdence interval, 6.7–12.8 mo) was shorter than the median 
time to ﬁrst distant site failure of 14.9 months (10.4–19.3 
mo). Moreover, among the 24 patients without diffuse skeletal 
metastasis on presentation, eight (33%) became candidates 
for SBRT. Of note, resolution of regional nodal disease was 
required for SBRT eligibility, and this was observed in 19 
(51%) out of the 37 patients who presented with node-positive 
disease before the initiation of TKI therapy.
DISCUSSION
To our knowledge, this is the ﬁrst study to report a 
detailed analysis of the patterns of initial disease progression 
after TKI therapy in patients with metastatic EGFR-mutant 
NSCLC. Our results demonstrate that relapse on TKI therapy 
occurs ﬁrst in originally involved sites of disease in approxi-
mately 50% of stage IV EGFR-mutant NSCLC patients. These 
ﬁndings are consistent with the common original site–only 
pattern of initial failure observed in the general population 
of NSCLC patients after systemic chemotherapy.25,39 Our data 
also suggest that failure in residual sites of original disease is 
likely to occur before the development of new sites of distant 
metastasis (Fig. 1A), providing a rationale for local therapy 
directed at original disease sites. In particular, primary lung 
tumors approximately 3 cm or larger are at high risk of pro-
gression and may beneﬁt from SBRT (Table 3; Fig. 1B).
Ten (20%) patients who presented with ﬁve or more sites 
of disease before TKI therapy achieved an adequate response 
to treatment to become candidates for consolidation SBRT 
(Table 4). In the majority (70%) of these patients, initial dis-
ease progression occurred in sites of original disease. In these 
patients, the median time to any failure was 11.8 months, 
which was shorter than the median time to DF of 14.9 months. 
The data are consistent with the idea that progression in sites 
of original disease is the direct consequence of the growth of 
residual disease containing TKI-resistant clones, and further, 
that distant metastases may arise in most cases only subsequent 
to the regrowth of these clones. Thus, consolidation SBRT for 
residual disease with the goal of eradicating drug-resistant 
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clones could conceivably delay distant disease progression 
and improve overall outcomes.15–17 In our analysis, the lung 
proved to be the most common site harboring residual disease 
while on TKI therapy (Table 4), highlighting the importance of 
thoracic SBRT for this concept. We note that although the sub-
set of patients with residual disease amenable to consolidation 
TABLE 1. Disease Characteristics at Presentation
Variable
All Patients (n = 49) Patients with OF (n = 23) Patients with DF (n = 10) Patients with ODF (n = 16)
n % n % n % n %
T stage
  T0 7 14.3 1 4.3 4 40 2 12.5
  T1 6 12.2 3 13.0 1 10 2 12.5
  T2 13 26.5 4 17.4 2 20 7 43.7
  T3 8 16.3 5 21.7 1 10 2 12.5
  T4 15 30.6 10 43.5 2 20 3 18.8
N stage
  N0 12 24.5 3 13.0 7 70 2 12.5
  N1 4 8.2 3 13.0 0 0 1 6.2
  N2 13 26.5 6 26.2 1 10 6 37.5
  N3 20 40.8 11 47.8 2 20 7 43.8
Organs harboring metastases
  Lung
   Yes 36 73.5 19 82.6 7 70 10 62.5
   No 13 26.5 4 17.4 3 30 6 37.5
  Brain
   Yes 16 32.7 7 30.4 3 30 6 37.5
   No 33 67.3 16 69.6 7 70 10 62.5
  Liver
   Yes 15 30.6 6 26.1 1 10 8 50
   No 34 69.4 17 73.9 9 90 8 50
  Adrenal
   Yes 9 18.4 7 30.4 0 0 2 12.5
   No 40 81.6 16 69.6 10 100 14 87.5
  Bone
   Yes 30 61.2 12 52.2 5 50 13 81.2
   No 19 38.8 11 47.8 5 50 3 18.8
  Other
   Yes 17 34.7 7 30.4 5 50 5 31.2
   No 32 65.3 16 69.6 5 50 11 68.8
Number of organs with metastases
  1 6 12.2 5 21.7 1 10 0 0
  2 16 32.7 8 34.8 4 40 4 25
  3 16 32.7 6 26.1 4 40 6 37.5
  4 5 10.2 0 0 1 10 4 25
  ≥5 6 12.2 4 17.4 0 0 2 12.5
Number of metastases
  1–5 8 16.3 3 13.0 4 40 1 6.2
  6–10 16 32.7 12 52.2 1 10 3 18.8
  11–15 11 22.4 2 8.7 3 30 6 37.5
  >15 14 28.6 6 26.1 2 20 6 37.5
TKI used
  Erlotinib 36 73.5 15 65.3 8 80 13 81.2
  Geﬁtinib 10 20.4 5 21.7 2 20 3 18.8
  Afatinib 3 6.1 3 13.0 0 0 0 0
OF, original site failure; DF, distant site failure; ODF, OF and DF combined; n, number; TKI, tyrosine kinase inhibitor.
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SBRT was relatively small, i.e., 20%, our criteria for SBRT 
eligibility were conservative (see Patients and Methods sec-
tion). Quite possibly, the fraction of EGFR-mutant patients 
who could beneﬁt from SBRT is greater than 20%. To this end, 
in additional cases where residual intrathoracic disease is not 
amenable to SBRT, for example, because of safety concerns, 
other local therapy forms such as hypofractionated radiation 
schedules may be employed to prevent progression.
Retrospective studies have demonstrated the safety and 
feasibility of combined therapy with EGFR TKI and SBRT in 
stage IV NSCLC patients. Weickhardt et al22 assessed the ben-
eﬁts of local ablative therapies including SBRT in 10 EGFR-
mutant patients with oligoprogressive disease on erlotinib. The 
authors showed more than 6 months of additional disease con-
trol in patients treated with SBRT upon disease progression. 
Similarly, Yu et al21 treated 18 oligoprogressive EGFR-mutant 
NSCLC patients with elective local therapy. Although only one 
patient was treated with SBRT to the lung, local therapy was 
associated with a median time to progression of 10 months 
and a median survival time of 41 months. Finally, Wang et al23 
treated 14 NSCLC patients (not limited to EGFR-mutant dis-
ease) with disease progression after platinum-based chemother-
apy with geﬁtinib and SBRT directed at progressive metastatic 
disease. The 1-year local control and overall survival rates were 
83.9% and 69.6%, respectively. Together, these studies reveal a 
potential role for the addition of  metastasis-directed SBRT in 
improving disease control and PFS in stage IV EGFR-mutant 
NSCLC patients treated with TKI.21–23
This study has the typical limitations of a retrospec-
tive analysis including a relatively small number of patients 
and potential for selection bias. Our ﬁndings, which should 
be viewed as hypothesis generating, suggest that consolida-
tion SBRT with continued TKI therapy has the potential to 
alter the natural history of disease progression and extend the 
PFS and overall survival of a subset of patients with stage IV 
EGFR-mutant NSCLC.25,40 This is different from the pub-
lished concept of SBRT for oligoprogressive disease to allow 
patients to stay on their current TKI regimen.34 Data presented 
in this report have informed the design of an ongoing pro-
spective study of consolidation residual disease-directed 
TABLE 2. Sites of Initial Failure
All Patients (n = 49) Patients with OF (n = 23) Patients with DF (n = 10) Patients with ODF (n = 16)
n % n % n % n %
Initial disease progression
  Primary only 11 22.5 11 47.8 0 0.0 0 0.0
  Metastasis only 27 55.0 4 17.4 10 10.0 13 81.2
  Primary and metastasis 11 22.5 8 34.8 0 0.0 3 18.8
Sites of initial failure
  Lung 30 61.2 18 78.3 4 40.0 8 50.0
  Liver 9 18.4 1 4.3 0 0.0 8 50.0
  Brain 2 4.0 0 0.0 1 10.0 1 6.3
  Bone 4 8.0 3 13.0 0 0.0 1 6.3
  Adrenal glands 2 4.0 2 8.7 0 0.0 0 0.0
  Regional lymph nodes 9 18.4 6 26.1 0 0.0 3 18.8
  Distant lymph nodes 3 6.1 0 0.0 2 20.0 1 6.3
  Other 12 24.5 2 8.7 4 40.0 6 37.5
OF, original site failure; DF, distant site failure; ODF, OF and DF combined; n, number.
FIGURE 1. Pattern of failure analysis. A, The cumulative 
incidence of any progression and each of the three patterns 
of failure, original site failure (OF), distant site failure (DF), 
and  simultaneous OF/DF (ODF) as a function of follow-up 
time. B, Estimated probability of each failure type (OF, DF, 
ODF) as a function of primary tumor size.
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SBRT following maximal response to ﬁrst-line TKI therapy 
in patients with oncogene-driven NSCLC (NCT02314364). 
Findings from this and other prospective studies will be nec-
essary to establish the beneﬁt of consolidation SBRT in the 
management of this disease.
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TABLE 3. Predictors of Original Disease Site Failure
Independent Variable SHR (±95% CL) UVA MVA
Primary size (cm) 1.31 (1.09, 1.57) p = 0.004 p = 0.002
Size of metastasis >3.5 cm (yes/no) 0.13 (0.02, 0.93) p = 0.04 p = 0.02
Lung metastases (yes/no) 2.10 (0.73, 6.02) p = 0.2
Brain metastases (yes/no) 0.93 (0.38, 2.30) p = 0.9
Liver metastases (yes/no) 0.88 (0.70, 1.12) p = 0.3
Adrenal metastases (yes/no) 2.84 (1.19, 6.80) p = 0.02 p = 0.004
Bone metastases (yes/no) 0.63 (0.28, 1.41) p = 0.3
Number of metastatic sites (n) 0.97 (0.92, 1.02) p = 0.3
SHR, subdistribution hazard ratio for univariate analysis; CL, conﬁdence limits; UVA, univariate analysis; MVA, multivariate analysis.
TABLE 4. Patients Classified as Eligible for Consolidation SBRT based on Residual Disease Extent
No. Primary Size (cm) Involved Organs (n) Metastases (n) Nodal Stage Max Response of T/N/M
Residual Disease At Max 
TKI Response First Failure
1 4 3 4 0 PR/NA/CR Primary DF
2 0 2 6 2 PR/CR/CR Primary ODF
3 6.2 5 >20 3 PR/CR/PR Primary, liver, adrenal OF
4 0 3 12 0 NA/NA/PR Spine OF
5 0 1 5 0 NA/NA/SD Lung DF
6 7 3 >20 2 PR/CR/CR Primary OF
7 4.3 1 4 0 PR/NA/CR Primary OF
8 7 2 6 2 SD/CR/PR Lung OF
9 2 2 6 1 PR/CR/SD Primary, lung OF
10 4 3 10 2 PR/CR/PR Primary, lung OF
n, number; Max, maximum; T, primary; N, nodes; M, metastases; CR, complete response; PR, partial response; SD, stable disease; NA, not applicable; OF, ﬁrst failure in original 
site; DF, ﬁrst failure in new distant site; ODF, simultaneous OF + DF; TKI, tyrosine kinase inhibitor; SBRT, stereotactic body radiation therapy.
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